(secondQuint)A Study to Evaluate Safety and Tolerability of JNJ-61178104 in Healthy Participants.

 This is a randomized, double-blind, placebo-controlled, single ascending dose, single site, interventional study.

 There will be 5 single ascending dose (SAD) IV cohorts and 1 SC cohort.

 Nine participants will be enrolled into each of 5 IV cohorts and 1 SC cohort and participants will be randomized at a ratio of 2:1 to receive JNJ-61178104 or placebo.

 The total duration of participants participation will be approximately 21 weeks including a Screening Visit up to 4 weeks prior to study drug administration.

 Participants will have an inpatient period consisting of 6 days/5 nights and will return to the study-site at Weeks 2, 3, 4, 5, 7, 9, 13, and 17.

 Participants will be evaluated for safety throughout the study.

.

 A Study to Evaluate Safety and Tolerability of JNJ-61178104 in Healthy Participants@highlight

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and immunogenicity of JNJ-61178104 following a single ascending Intravenous (IV) dose administration and a single Subcutaneous (SC) dose administration in healthy participants.

